People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07939529. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Study identification
- NCT ID
- NCT07939529
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2028 (Estimated)
- Primary completion
- Aug 31, 2029 (Estimated)
- Completion
- Oct 26, 2030 (Estimated)
- Last update posted
- Nov 16, 2026
2028 – 2030
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama (Site ID: 31788) | Birmingham | Alabama | 35222 | — |
| University of California, Los Angeles CARE Center (Site ID: 601) | Los Angeles | California | 90035 | — |
| UCSD Antiviral Research Center (Site ID: 701) | San Diego | California | 92103 | — |
| University of California, San Francisco (Site ID: 801) | San Francisco | California | 94110 | — |
| Harbor University of California Los Angeles Center (Site ID: 603) | Torrance | California | 90502-2052 | — |
| University of Colorado Hospital (Site ID: 6101) | Aurora | Colorado | 80045 | — |
| Whitman-Walker Institute, Inc. (Site ID: 21791) | Washington D.C. | District of Columbia | 20032 | — |
| Northwestern University (Site ID: 2701) | Chicago | Illinois | 60611 | — |
| Johns Hopkins University (Site ID: 201) | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital (Site ID: 101) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107) | Boston | Massachusetts | 02115 | — |
| New Jersey Medical School Clinical Research Center (Site ID: 31786) | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea (Site ID: 7804) | New York | New York | 10010 | — |
| Weill Cornell Uptown (Site ID: 7803) | New York | New York | 10010 | — |
| Columbia Physicians & Surgeons (P&S) (Site ID: 30329) | New York | New York | 10032 | — |
| Chapel Hill (Site ID: 3201) | Chapel Hill | North Carolina | 27599-7215 | — |
| Greensboro (Site ID: 3203) | Greensboro | North Carolina | 27401-1020 | — |
| Cincinnati Clinical Research Site (Site ID: 2401) | Cincinnati | Ohio | 45267-0405 | — |
| Case Clinical Research Site (Site ID: 2501) | Cleveland | Ohio | 44106 | — |
| Ohio State University (Site ID: 2301) | Columbus | Ohio | 43210 | — |
| University of Pittsburgh (Site ID: 1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) (Site ID: 3652) | Nashville | Tennessee | 37204 | — |
| Houston Advancing Research Team (Site ID: 31473) | Houston | Texas | 77030 | — |
| University of Washington Positive Research (Site ID: 1401) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07939529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.